ArticleCancer biology & medicine2016
Role of microRNAs in inflammation-associated liver cancer.
Article in Cancer biology & medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Space radiation and microgravity as models of accelerated aging: modulation of hepatic miRNA-TGF-β networks associated with senescence and fibrosis.GeroScience · 2026Article
- Key oncogenes and candidate drugs for hepatitis-B-driven hepatocellular carcinoma progression.Discover oncology · 2025Article
- Functional hydrogels for hepatocellular carcinoma: therapy, imaging, and in vitro model.Journal of nanobiotechnology · 2024Review
- LncRNA n339260 functions in hepatocellular carcinoma progression via regulation of miRNA30e-5p/TP53INP1 expression.Journal of gastroenterology · 2022Article
- Review
- Pathogenetic Role and Clinical Implications of Regulatory RNAs in Biliary Tract Cancer.Cancers · 2020Review
- Circulating microRNAs associated with liver fibrosis in chronic hepatitis C patients.Biochemistry and biophysics reports · 2020Article
- Targeting STAT3 in Cancer Immunotherapy.Molecular cancer · 2020Review
- Anticancer Effects ofOncology research · 2019Article
- MicroRNA Expression in Focal Nodular Hyperplasia in Comparison with Cirrhosis and Hepatocellular Carcinoma.Pathology oncology research : POR · 2019Article
- Curcumin Inhibits Proliferation of Epstein-Barr Virus-Associated Human Nasopharyngeal Carcinoma Cells by Inhibiting EBV Nuclear Antigen 1 Expression.BioMed research international · 2019Article
- Roles of NF-κB Signaling in the Regulation of miRNAs Impacting on Inflammation in Cancer.Biomedicines · 2018Review
- MicroRNA-149* suppresses hepatic inflammatory response through antagonizing STAT3 signaling pathway.Oncotarget · 2017Article
- Cancer of the Liver and its Relationship with Diabetes mellitus.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver cancer, primarily hepatocellular carcinoma (HCC), is a major cause of cancer-related death worldwide. HCC is a suitable model of inflammation-induced cancer because more than 90% of HCC cases are caused by liver damage and chronic inflammation. Several inflammatory response pathways, such as NF-κB and JAK/STAT3 signaling pathways, play roles in the crosstalk between inflammation and HCC. MicroRNAs (miRNAs) are evolutionarily conserved, short endogenous, non-coding single-stranded RNAs that are involved in various biological and pathological processes by regulating gene expression and protein translation. Evidence showed that miRNAs play a pivotal role in hepatitis virus infection and serve as promoters or inhibitors of inflammatory response. Aberrant miRNA was observed during liver inflammation and HCC. Many dysregulated miRNAs modulate the initiation and progression of inflammation-induced HCC. This review summarizes the role and functions of miRNAs in inflammation-associated HCC, as well as the designed therapeutics targeting miRNAs to treat liver inflammation and HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.